DataVXJournal of Nanoparticle ResearchPaper
journal article·2025-04

Ischemic strokes: exploring the challenges of translating nanomedicine into clinical practice

Thibault de La Taille, Diana Doukhi, Mikael Mazighi, Cédric Chauvierre

Journal of Nanoparticle Research· Volume 27· Issue 4
Publisher page
Bibliographic record

Abstract

No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.

Source: Not provided · Quality: missing

Research context

Nanomaterials

OpenAlex topics: Acute Ischemic Stroke Management · Nanoparticle-Based Drug Delivery · Nanoparticles: synthesis and applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (87)

Show source-provided references
1. GBD 2019 Stroke Collaborators (2021) Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol 20:795–820. https://doi.org/10.1016/S1474-4422(21)00252-010.1016/S1474-4422(21)00252-0 ↗
2. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group (1995) Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333:1581–1587. https://doi.org/10.1056/NEJM19951214333240110.1056/NEJM199512143332401 ↗
3. Goyal M, Demchuk AM, Menon BK et al (2015) Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med 372:1019–1030. https://doi.org/10.1056/NEJMoa141490510.1056/NEJMoa1414905 ↗
4. Berkhemer OA, Fransen PSS, Beumer D et al (2015) A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med 372:11–20. https://doi.org/10.1056/NEJMoa141158710.1056/NEJMoa1411587 ↗
5. Saver JL, Goyal M, Bonafe A et al (2015) Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med 372:2285–2295. https://doi.org/10.1056/NEJMoa141506110.1056/NEJMoa1415061 ↗
6. Jovin TG, Chamorro A, Cobo E et al (2015) Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med 372:2296–2306. https://doi.org/10.1056/NEJMoa150378010.1056/NEJMoa1503780 ↗
7. Campbell BCV, Mitchell PJ, Kleinig TJ et al (2015) Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med 372:1009–1018. https://doi.org/10.1056/NEJMoa141479210.1056/NEJMoa1414792 ↗
8. Hacke W, Kaste M, Bluhmki E et al (2008) Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 359:1317–1329. https://doi.org/10.1056/NEJMoa080465610.1056/NEJMoa0804656 ↗
9. Powers WJ, Rabinstein AA, Ackerson T et al (2019) Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 50:e344–e418. https://doi.org/10.1161/STR.000000000000021110.1161/STR.0000000000000211 ↗
10. Berge E, Whiteley W, Audebert H et al (2021) European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke. Eur Stroke J 6:I–LXII. https://doi.org/10.1177/239698732198986510.1177/2396987321989865 ↗
11. Thomalla G, Simonsen CZ, Boutitie F et al (2018) MRI-guided thrombolysis for stroke with unknown time of onset. N Engl J Med 379:611–622. https://doi.org/10.1056/NEJMoa180435510.1056/NEJMoa1804355 ↗
12. Ma H, Campbell BCV, Parsons MW et al (2019) Thrombolysis guided by perfusion imaging up to 9 hours after onset of stroke. N Engl J Med 380:1795–1803. https://doi.org/10.1056/NEJMoa181304610.1056/NEJMoa1813046 ↗
13. Alamowitch S, Turc G, Palaiodimou L et al (2023) European Stroke Organisation (ESO) expedited recommendation on tenecteplase for acute ischaemic stroke. Eur Stroke J 8:8–54. https://doi.org/10.1177/2396987322115002210.1177/23969873221150022 ↗
14. de Havenon A, Sheth K, Johnston KC et al (2021) Acute ischemic stroke interventions in the United States and racial, socioeconomic, and geographic disparities. Neurology 97:e2292–e2303. https://doi.org/10.1212/WNL.000000000001294310.1212/WNL.0000000000012943 ↗
15. Seners P, Turc G, Maïer B et al (2016) Incidence and predictors of early recanalization after intravenous thrombolysis. Stroke 47:2409–2412. https://doi.org/10.1161/STROKEAHA.116.01418110.1161/STROKEAHA.116.014181 ↗
16. Albers GW, Marks MP, Kemp S et al (2018) Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. N Engl J Med 378:708–718. https://doi.org/10.1056/NEJMoa171397310.1056/NEJMoa1713973 ↗
17. Nogueira RG, Jadhav AP, Haussen DC et al (2018) Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med 378:11–21. https://doi.org/10.1056/NEJMoa170644210.1056/NEJMoa1706442 ↗
18. Turc G, Bhogal P, Fischer U et al (2023) European Stroke Organisation (ESO) - European Society for Minimally Invasive Neurological Therapy (ESMINT) guidelines on mechanical thrombectomy in acute ischemic stroke. J Neurointerventional Surg 15:e8. https://doi.org/10.1136/neurintsurg-2018-01456910.1136/neurintsurg-2018-014569 ↗
19. Ehrlich P (1960) Experimental researches on specific therapy: on immunity with special reference to the relationship between distribution and action of antigens**[reprinted (with amendments by the Ed.) from The Harben Lectures for 1907 of the Royal Institute of Public Health, London: Lewis, 190810.5962/bhl.title.28293 ↗
20. cf. Bibl. 200 and 181.]: FIRST HARBEN LECTURE††[Delivered in London, 5 June 1907.]. In: Himmelweit F (ed) The collected papers of Paul Ehrlich. Pergamon, pp 106-117
21. Blanco E, Shen H, Ferrari M (2015) Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol 33:941–951. https://doi.org/10.1038/nbt.333010.1038/nbt.3330 ↗
22. Navya PN, Daima HK (2016) Rational engineering of physicochemical properties of nanomaterials for biomedical applications with nanotoxicological perspectives. Nano Converg 3:1. https://doi.org/10.1186/s40580-016-0064-z10.1186/s40580-016-0064-z ↗
23. Müller K, Fedosov DA, Gompper G (2014) Margination of micro- and nano-particles in blood flow and its effect on drug delivery. Sci Rep 4:4871. https://doi.org/10.1038/srep0487110.1038/srep04871 ↗
24. Sarfati P, de La Taille T, Portioli C et al (2024) REVIEW: “ISCHEMIC STROKE: from fibrinolysis to functional recovery” Nanomedicine: emerging approaches to treat ischemic stroke. Neuroscience 550:102–113. https://doi.org/10.1016/j.neuroscience.2023.11.03510.1016/j.neuroscience.2023.11.035 ↗
25. Wang Y, Jian C, Long Y et al (2023) H2O2-triggered “off/on signal” nanoparticles target P-selectin for the non-invasive and contrast-enhanced theranostics for arterial thrombosis. Acta Biomater 158:769–781. https://doi.org/10.1016/j.actbio.2022.12.02610.1016/j.actbio.2022.12.026 ↗
26. Deuchar GA, van Kralingen JC, Work LM et al (2019) Preclinical validation of the therapeutic potential of Glasgow oxygen level dependent (GOLD) technology: a theranostic for acute stroke. Transl Stroke Res 10:583–595. https://doi.org/10.1007/s12975-018-0679-y10.1007/s12975-018-0679-y ↗
27. Ye Q, Zheng D, Chen K et al (2023) Phase-change based oxygen carriers improve acute cerebral hypoxia. Small n/a:2309180:2309180. https://doi.org/10.1002/smll.20230918010.1002/smll.202309180 ↗
28. Fournier L, Abioui-Mourgues M, Chabouh G et al (2023) rtPA-loaded fucoidan polymer microbubbles for the targeted treatment of stroke. Biomaterials 303:122385. https://doi.org/10.1016/j.biomaterials.2023.12238510.1016/j.biomaterials.2023.122385 ↗
29. Ma J, Zhang S, Liu J et al (2019) Targeted drug delivery to stroke via chemotactic recruitment of nanoparticles coated with membrane of engineered neural stem cells. Small 15:1902011. https://doi.org/10.1002/smll.20190201110.1002/smll.201902011 ↗
30. Han M, Zhang Z, Liu Z et al (2023) Three-dimensional-cultured MSC-derived exosome with hydrogel for cerebral ischemia repair. Biomater Adv 149:213396. https://doi.org/10.1016/j.bioadv.2023.21339610.1016/j.bioadv.2023.213396 ↗
31. Son JP, Kim EH, Shin EK et al (2023) Mesenchymal stem cell-extracellular vesicle therapy for stroke: scalable production and imaging biomarker studies. Stem Cells Transl Med 12:459–473. https://doi.org/10.1093/stcltm/szad03410.1093/stcltm/szad034 ↗
32. Li C, Zhao Z, Luo Y et al (2021) Macrophage-disguised manganese dioxide nanoparticles for neuroprotection by reducing oxidative stress and modulating inflammatory microenvironment in acute ischemic stroke. Adv Sci 8:2101526. https://doi.org/10.1002/advs.20210152610.1002/advs.202101526 ↗
33. Tian T, Cao L, He C et al (2021) Targeted delivery of neural progenitor cell-derived extracellular vesicles for anti-inflammation after cerebral ischemia. Theranostics 11:6507–6521. https://doi.org/10.7150/thno.5636710.7150/thno.56367 ↗
34. Zhang Y, Liu Y, Zhang T et al (2021) Targeted thrombolytic therapy with metal–organic-framework-derived carbon based platforms with multimodal capabilities. ACS Appl Mater Interfaces 13:24453–24462. https://doi.org/10.1021/acsami.1c0313410.1021/acsami.1c03134 ↗
35. Zhang H, Zhao Z, Sun S et al (2023) Molecularly self-fueled nano-penetrator for nonpharmaceutical treatment of thrombosis and ischemic stroke. Nat Commun 14:255. https://doi.org/10.1038/s41467-023-35895-510.1038/s41467-023-35895-5 ↗
36. Zhang F, Liu Y, Lei J et al (2019) Metal–organic-framework-derived carbon nanostructures for site-specific dual-modality photothermal/photodynamic thrombus therapy. Adv Sci 6:1901378. https://doi.org/10.1002/advs.20190137810.1002/advs.201901378 ↗
37. Shekhar H, Kleven RT, Peng T et al (2019) In vitro characterization of sonothrombolysis and echocontrast agents to treat ischemic stroke. Sci Rep 9:9902. https://doi.org/10.1038/s41598-019-46112-z10.1038/s41598-019-46112-z ↗
38. Choi W, Key J, Youn I et al (2022) Cavitation-assisted sonothrombolysis by asymmetrical nanostars for accelerated thrombolysis. J Controlled Release 350:870–885. https://doi.org/10.1016/j.jconrel.2022.09.00810.1016/j.jconrel.2022.09.008 ↗
39. Xu J, Zhang Y, Xu J et al (2020) Engineered nanoplatelets for targeted delivery of plasminogen activators to reverse thrombus in multiple mouse thrombosis models. Adv Mater 32:1905145. https://doi.org/10.1002/adma.20190514510.1002/adma.201905145 ↗
40. Yu W, Yin N, Yang Y et al (2022) Rescuing ischemic stroke by biomimetic nanovesicles through accelerated thrombolysis and sequential ischemia-reperfusion protection. Acta Biomater 140:625–640. https://doi.org/10.1016/j.actbio.2021.12.00910.1016/j.actbio.2021.12.009 ↗
41. Huang L, Wang J, Huang S et al (2019) Polyacrylic acid-coated nanoparticles loaded with recombinant tissue plasminogen activator for the treatment of mice with ischemic stroke. Biochem Biophys Res Commun 516:565–570. https://doi.org/10.1016/j.bbrc.2019.06.07910.1016/j.bbrc.2019.06.079 ↗
42. Zenych A, Jacqmarcq C, Aid R et al (2021) Fucoidan-functionalized polysaccharide submicroparticles loaded with alteplase for efficient targeted thrombolytic therapy. Biomaterials 277:121102. https://doi.org/10.1016/j.biomaterials.2021.12110210.1016/j.biomaterials.2021.121102 ↗
43. Lippi G, Franchini M, Targher G (2011) Arterial thrombus formation in cardiovascular disease. Nat Rev Cardiol 8:502–512. https://doi.org/10.1038/nrcardio.2011.9110.1038/nrcardio.2011.91 ↗
44. Ho-Tin-Noé B, Desilles J-P, Mazighi M (2023) Thrombus composition and thrombolysis resistance in stroke. Res Pract Thromb Haemost 7:100178. https://doi.org/10.1016/j.rpth.2023.10017810.1016/j.rpth.2023.100178 ↗
45. Fukuta T, Ikeda-Imafuku M, Iwao Y (2023) Development of edaravone ionic liquids and their application for the treatment of cerebral ischemia/reperfusion injury. Mol Pharm 20:3115–3126. https://doi.org/10.1021/acs.molpharmaceut.3c0010310.1021/acs.molpharmaceut.3c00103 ↗
46. Liu S, Xu J, Liu Y et al (2022) Neutrophil-biomimetic “nanobuffer” for remodeling the microenvironment in the infarct core and protecting neurons in the penumbra via neutralization of detrimental factors to treat ischemic stroke. ACS Appl Mater Interfaces 14:27743–27761. https://doi.org/10.1021/acsami.2c0902010.1021/acsami.2c09020 ↗
47. Huang Z, Qian K, Chen J et al (2022) A biomimetic zeolite-based nanoenzyme contributes to neuroprotection in the neurovascular unit after ischaemic stroke via efficient removal of zinc and ROS. Acta Biomater 144:142–156. https://doi.org/10.1016/j.actbio.2022.03.01810.1016/j.actbio.2022.03.018 ↗
48. Ma R, Xie Q, Li Y et al (2020) Animal models of cerebral ischemia: a review. Biomed Pharmacother 131:110686. https://doi.org/10.1016/j.biopha.2020.11068610.1016/j.biopha.2020.110686 ↗
49. McBride DW, Zhang JH (2017) Precision stroke animal models: the permanent MCAO model should be the primary model, not transient MCAO. Transl Stroke Res 8:397–404. https://doi.org/10.1007/s12975-017-0554-210.1007/s12975-017-0554-2 ↗
50. Shi J, Yu W, Xu L et al (2020) Bioinspired nanosponge for salvaging ischemic stroke via free radical scavenging and self-adapted oxygen regulating. Nano Lett 20:780–789. https://doi.org/10.1021/acs.nanolett.9b0497410.1021/acs.nanolett.9b04974 ↗
51. Tang L, Yin Y, Liu H et al (2024) Blood–brain barrier-penetrating and lesion-targeting nanoplatforms inspired by the pathophysiological features for synergistic ischemic stroke therapy. Adv Mater 2312897:2312897. https://doi.org/10.1002/adma.20231289710.1002/adma.202312897 ↗
52. Zhou M, Zhang T, Zhang B et al (2022) A DNA nanostructure-based neuroprotectant against neuronal apoptosis via inhibiting Toll-like receptor 2 signaling pathway in acute ischemic stroke. ACS Nano 16:1456–1470. https://doi.org/10.1021/acsnano.1c0962610.1021/acsnano.1c09626 ↗
53. Ashafaq M, Intakhab Alam M, Khan A et al (2021) Nanoparticles of resveratrol attenuates oxidative stress and inflammation after ischemic stroke in rats. Int Immunopharmacol 94:107494. https://doi.org/10.1016/j.intimp.2021.10749410.1016/j.intimp.2021.107494 ↗
54. Liao J, Li Y, Fan L et al (2024) Bioactive ceria nanoenzymes target mitochondria in reperfusion injury to treat ischemic stroke. ACS Nano 18:5510–5529. https://doi.org/10.1021/acsnano.3c1098210.1021/acsnano.3c10982 ↗
55. He L, Huang G, Liu H et al (2020) Highly bioactive zeolitic imidazolate framework-8-capped nanotherapeutics for efficient reversal of reperfusion-induced injury in ischemic stroke. Sci Adv 6:eaay9751. https://doi.org/10.1126/sciadv.aay975110.1126/sciadv.aay9751 ↗
56. Yan BC, Cao J, Liu J et al (2021) Dietary Fe3O4 nanozymes prevent the injury of neurons and blood–brain barrier integrity from cerebral ischemic stroke. ACS Biomater Sci Eng 7:299–310. https://doi.org/10.1021/acsbiomaterials.0c0131210.1021/acsbiomaterials.0c01312 ↗
57. Li Y, Liu B, Zhao T et al (2023) Comparative study of extracellular vesicles derived from mesenchymal stem cells and brain endothelial cells attenuating blood–brain barrier permeability via regulating Caveolin-1-dependent ZO-1 and Claudin-5 endocytosis in acute ischemic stroke. J Nanobiotechnology 21:70. https://doi.org/10.1186/s12951-023-01828-z10.1186/s12951-023-01828-z ↗
58. Zhang A, Li J, Wang S et al (2021) Rapid and improved oral absorption of N-butylphthalide by sodium cholate-appended liposomes for efficient ischemic stroke therapy. Drug Deliv 28:2469–2479. https://doi.org/10.1080/10717544.2021.200067810.1080/10717544.2021.2000678 ↗
59. Alexandrov AV, Köhrmann M, Soinne L et al (2019) Safety and efficacy of sonothrombolysis for acute ischaemic stroke: a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Neurol 18:338–347. https://doi.org/10.1016/S1474-4422(19)30026-210.1016/S1474-4422(19)30026-2 ↗
60. Alexandrov AV, Demchuk AM, Felberg RA et al (2000) High rate of complete recanalization and dramatic clinical recovery during tPA infusion when continuously monitored With 2-MHz transcranial Doppler monitoring. Stroke 31:610–614. https://doi.org/10.1161/01.STR.31.3.61010.1161/01.STR.31.3.610 ↗
61. Eggers J, Koch B, Meyer K et al (2003) Effect of ultrasound on thrombolysis of middle cerebral artery occlusion. Ann Neurol 53:797–800. https://doi.org/10.1002/ana.1059010.1002/ana.10590 ↗
62. Tsivgoulis G, Eggers J, Ribo M et al (2010) Safety and efficacy of ultrasound-enhanced thrombolysis. Stroke 41:280–287. https://doi.org/10.1161/STROKEAHA.109.56330410.1161/STROKEAHA.109.563304 ↗
63. Ricci S, Dinia L, Del Sette M et al (2012) Sonothrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev CD008348. https://doi.org/10.1002/14651858.CD008348.pub210.1002/14651858.CD008348.pub2 ↗
64. Daffertshofer M, Gass A, Ringleb P et al (2005) Transcranial low-frequency ultrasound-mediated thrombolysis in brain ischemia. Stroke 36:1441–1446. https://doi.org/10.1161/01.STR.0000170707.86793.1a10.1161/01.STR.0000170707.86793.1a ↗
65. Brown AT, Arthur MC, Nix JS et al (2014) Dodecafluoropentane emulsion (DDFPe) decreases stroke size and improves neurological scores in a permanent occlusion rat stroke model. Open Neurol J 8:27–33. https://doi.org/10.2174/1874205X0140801002710.2174/1874205X01408010027 ↗
66. Woods SD, Skinner RD, Ricca AM et al (2013) Progress in dodecafluoropentane emulsion as a neuroprotective agent in a rabbit stroke model. Mol Neurobiol 48:363–367. https://doi.org/10.1007/s12035-013-8495-610.1007/s12035-013-8495-6 ↗
67. Culp WC, Onteddu SS, Brown A et al (2019) Dodecafluoropentane emulsion in acute ischemic stroke: a phase Ib/II randomized and controlled dose-escalation trial. J Vasc Interv Radiol JVIR 30:1244-1250.e1. https://doi.org/10.1016/j.jvir.2019.04.02010.1016/j.jvir.2019.04.020 ↗
68. Molina CA, Ribo M, Rubiera M et al (2006) Microbubble administration accelerates clot lysis during continuous 2-MHz ultrasound monitoring in stroke patients treated with intravenous tissue plasminogen activator. Stroke 37:425–429. https://doi.org/10.1161/01.STR.0000199064.94588.3910.1161/01.STR.0000199064.94588.39 ↗
69. Nacu A, Kvistad CE, Logallo N et al (2015) A pragmatic approach to sonothrombolysis in acute ischaemic stroke: the Norwegian randomised controlled sonothrombolysis in acute stroke study (NOR-SASS). BMC Neurol 15:110. https://doi.org/10.1186/s12883-015-0359-410.1186/s12883-015-0359-4 ↗
70. Saleh A, Schroeter M, Ringelstein A et al (2007) Iron oxide particle-enhanced MRI suggests variability of brain inflammation at early stages after ischemic stroke. Stroke 38:2733–2737. https://doi.org/10.1161/STROKEAHA.107.48178810.1161/STROKEAHA.107.481788 ↗
71. Imaizumi S, Woolworth V, Fishman RA, Chan PH (1990) Liposome-entrapped superoxide dismutase reduces cerebral infarction in cerebral ischemia in rats. Stroke 21:1312–1317. https://doi.org/10.1161/01.str.21.9.131210.1161/01.str.21.9.1312 ↗
72. Soenen S, Rivera Gil P, Montenegro JM et al (2011) Cellular toxicity of inorganic nanoparticles: common aspects and guidelines for improved nanotoxicity evaluation. Nano Today 6:446–465. https://doi.org/10.1016/j.nantod.2011.08.00110.1016/j.nantod.2011.08.001 ↗
73. Halwani AA (2022) Development of pharmaceutical nanomedicines: from the bench to the market. Pharmaceutics 14:106. https://doi.org/10.3390/pharmaceutics1401010610.3390/pharmaceutics14010106 ↗
74. Namiot ED, Sokolov AV, Chubarev VN et al (2023) Nanoparticles in clinical trials: analysis of clinical trials, FDA approvals and use for COVID-19 vaccines. Int J Mol Sci 24:787. https://doi.org/10.3390/ijms2401078710.3390/ijms24010787 ↗
75. Shan X, Gong X, Li J et al (2022) Current approaches of nanomedicines in the market and various stage of clinical translation. Acta Pharm Sin B 12:3028–3048. https://doi.org/10.1016/j.apsb.2022.02.02510.1016/j.apsb.2022.02.025 ↗
76. Zhong L, Li Y, Xiong L et al (2021) Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduct Target Ther 6:201. https://doi.org/10.1038/s41392-021-00572-w10.1038/s41392-021-00572-w ↗
77. Oude Blenke E, Örnskov E, Schöneich C et al (2023) The storage and in-use stability of mRNA vaccines and therapeutics: not a cold case. J Pharm Sci 112:386–403. https://doi.org/10.1016/j.xphs.2022.11.00110.1016/j.xphs.2022.11.001 ↗
78. Hoogendijk E, Swider E, Staal AHJ et al (2020) Continuous-flow production of perfluorocarbon-loaded polymeric nanoparticles: from the bench to clinic. ACS Appl Mater Interfaces 12:49335–49345. https://doi.org/10.1021/acsami.0c1202010.1021/acsami.0c12020 ↗
79. Gurewich V (2016) Therapeutic fibrinolysis: how efficacy and safety can be improved. J Am Coll Cardiol 68:2099–2106. https://doi.org/10.1016/j.jacc.2016.07.78010.1016/j.jacc.2016.07.780 ↗
80. de La Taille T, Sarfati P, Aid R et al (2025) Microemulsion-inspired polysaccharide nanoparticles for an advanced targeted thrombolytic treatment. ACS Nano. https://doi.org/10.1021/acsnano.4c1704910.1021/acsnano.4c17049 ↗
81. Peña-Martínez C, Durán-Laforet V, García-Culebras A et al (2019) Pharmacological modulation of neutrophil extracellular traps reverses thrombotic stroke tPA (tissue-type plasminogen activator) resistance. Stroke 50:3228–3237. https://doi.org/10.1161/STROKEAHA.119.02684810.1161/STROKEAHA.119.026848 ↗
82. Fitzgerald ST, Liu Y, Dai D et al (2021) Novel human acute ischemic stroke blood clot analogs for in vitro thrombectomy testing. AJNR Am J Neuroradiol 42:1250–1257. https://doi.org/10.3174/ajnr.A710210.3174/ajnr.A7102 ↗
83. Lapergue B, Blanc R, Costalat V et al (2021) Effect of thrombectomy with combined contact aspiration and stent retriever vs stent retriever alone on revascularization in patients with acute ischemic stroke and large vessel occlusion: the ASTER2 randomized clinical trial. JAMA 326:1158–1169. https://doi.org/10.1001/jama.2021.1382710.1001/jama.2021.13827 ↗
84. Rai AT, Link PS, Domico JR (2023) Updated estimates of large and medium vessel strokes, mechanical thrombectomy trends, and future projections indicate a relative flattening of the growth curve but highlight opportunities for expanding endovascular stroke care. J NeuroInterventional Surg 15:e349–e355. https://doi.org/10.1136/jnis-2022-01977710.1136/jnis-2022-019777 ↗
85. Yu S, Li D, Shi A et al (2023) Multidrug-loaded liposomes prevent ischemic stroke through intranasal administration. Biomed Pharmacother 162:114542. https://doi.org/10.1016/j.biopha.2023.11454210.1016/j.biopha.2023.114542 ↗
86. Ducroux C, Di Meglio L, Loyau S et al (2018) Thrombus neutrophil extracellular traps content impair tPA-induced thrombolysis in acute ischemic stroke. Stroke 49:754–757. https://doi.org/10.1161/STROKEAHA.117.01989610.1161/STROKEAHA.117.019896 ↗
87. Okada T, Suzuki H, Travis ZD, Zhang JH (2020) The stroke-induced blood-brain barrier disruption: current progress of inspection technique, mechanism, and therapeutic target. Curr Neuropharmacol 18:1187–1212. https://doi.org/10.2174/1570159X1866620052814330110.2174/1570159X18666200528143301 ↗